Evidence map›Paper›PMID 32411770›Full record

ArticleAnnals of translational medicine2020

Clinical characteristics of 60 discharged cases of 2019 novel coronavirus-infected pneumonia in Taizhou, China.

Yongpo Jiang, Susu He, Chao Zhang, Xiaodan Wang, Xi Chen, Yingying Jin, Zebao He, Minjie Cai, Zongmei Lin, Lingjun Ying and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023
    Pooled it
  2. Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2021
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yongpo JiangDepartment of Critical Care Medicine, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Taizhou 317000, China.
Susu HeDepartment of Respiratory Medicine, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Taizhou 317000, China.
Chao ZhangDepartment of Critical Care Medicine, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Taizhou 317000, China.
Xiaodan WangDepartment of Anesthesiology, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Taizhou 317000, China.
Xi ChenDepartment of Respiratory Medicine, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Taizhou 317000, China.
Yingying JinDepartment of Critical Care Medicine, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Taizhou 317000, China.
Zebao HeDepartment of Infectious Diseases, Taizhou Enze Medical Center (Group) Enze Hospital, Taizhou Public Health Center, Taizhou 318050, China.
Minjie CaiDepartment of Critical Care Medicine, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Taizhou 317000, China.
Zongmei LinDepartment of Infectious Diseases, Taizhou Enze Medical Center (Group) Enze Hospital, Taizhou Public Health Center, Taizhou 318050, China.
Lingjun YingDepartment of Infectious Diseases, Taizhou Enze Medical Center (Group) Enze Hospital, Taizhou Public Health Center, Taizhou 318050, China.
Jianli MouDepartment of Infectious Diseases, Taizhou Enze Medical Center (Group) Enze Hospital, Taizhou Public Health Center, Taizhou 318050, China.
Haihong ZhaoDepartment of Infectious Diseases, Taizhou Enze Medical Center (Group) Enze Hospital, Taizhou Public Health Center, Taizhou 318050, China.
Ronghai LinDepartment of Critical Care Medicine, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Taizhou 317000, China.
Sheng ZhangDepartment of Critical Care Medicine, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Taizhou 317000, China.
Xiaomai WuDepartment of Respiratory Medicine, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Taizhou 317000, China.
Haixiao ChenDepartment of orthopedics, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Taizhou 317000, China.
Dongqing LvDepartment of Respiratory Medicine, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Taizhou 317000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe number of patients with pneumonia stemming from the 2019 novel coronavirus (COVID-19) infection has increased rapidly. However, the clinical characteristics of discharged patients remain little known. Here, we attempt to describe the clinical characteristics and treatment experiences of discharged cases from Taizhou, China.

methodsA total of 60 patients with COVID-19-infected pneumonia who were discharged from Taizhou Enze Medical Center (Group), from January 31, 2020, to February 16, 2020, were included in the analysis. The discharge criteria were based on the New Coronavirus Pneumonia Prevention and Control Program (Fifth Edition, China).

resultsOf the 60 patients, the median age was 41 years, and 58.3% were male. Only 13.3% of patients were identified as having severe novel coronavirus pneumonia. All patients received combined antiviral treatment on admission, including β-interferon, lopinavir/tonavir, Abidol and oseltamivir. All patients with severe conditions received gamma globulin and hormone therapy. No patients had endotracheal intubation or died. The median duration from symptom onset to hospitalization was 3 (range, 0-15) days. The median duration of COVID-19 shedding was 14 (range, 5-26) days, and the median duration of hospital stay was 15 (range, 7-23) days.

conclusionsEarly therapy and comprehensive therapy are key to the outcome for patients with COVID-19-infected pneumonia, especially for those with severe pneumonia. TRIAL REGISTRATION NUMBER: ChiCTR2000029866.

Indexed as

2019 novel coronavirus (COVID-19)2019 novel coronavirus-infection pneumonia (COVID-19-infection pneumoniaantiviralearly treatment

Identifiers

PMID32411770
PMCPMC7214894

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.